Business
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up remained relapse-free vs. 1/4 (25%) in the control arm TSC-101 was well-tolerated with no dose-limiting toxicities observed Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc. on Monday, December 8, at 8:00 a.m. ET WALTHAM, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, I
About this update from Tscan Therapeutics, Inc.
[{"type":"image","alt":"TScan Therapeutics, Inc.","displaySize":"","headline":null,"caption":"TScan Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":88,"url":"https://media.zenfs.com/en/globenewswire.com/c363c98946cf506a90ed1ea98d7db5fd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oJd2gbDue06Bt1BDI6AStQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c363c98946cf506a90ed1ea98d7db5fd","width":300,"height":88}},"lazy":false},{"type":"text","content":"Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52)","length":127,"tagName":"p"},{"type":"text","content":"3/3 (100%) of TSC-101-treated patients who reached two-year follow-up remained relapse-free vs. 1/4 (25%) in the control arm","length":124,"tagName":"p"},{"type":"text","content":"TSC-101 was well-tolerated with no dose-limiting toxicities observed","length":68,"tagName":"p"},{"type":"text","content":"Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc. on Monday, December 8, at 8:00 a.m. ET","length":106,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced updated results from the ongoing ALLOHA™ Phase 1 trial (NCT05473910) of TSC-101 in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). The data is being featured in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.","length":587,"tagName":"p"},{"type":"text","content":"“These updated data from our Phase 1 study continue to highlight a positive safety and efficacy profile of TSC-101 in patients with heme malignancies undergoing allogeneic HCT. All three patients who reached two years of follow-up have no detectable disease as they have remained relapse-free and in complete donor chimerism,” said Chrystal U. Louis, M.D., Chief Medical Officer. “Additionally, there have been no dose-limiting toxicities and patients who received TSC-101 continue to show improved relapse-free and overall survival compared...